SCHEMBL3488403

SCHEMBL3488403

Cc1ccc(Oc2ccc(N)c(CNC(=O)O)c2)cc1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.42
HTR2A P28223 4/20 0.42
SLC6A4 P31645 4/20 0.42
KCNH2 Q12809 3/20 0.42
TDP1 Q9NUW8 3/20 0.41
KMT2A Q03164 4/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
LMNA P02545 1/20 0.40
GFER P55789 1/20 0.40
HPGD P15428 3/20 0.40
MEN1 O00255 3/20 0.40
MAPT P10636 2/20 0.40
PPARG P37231 1/20 0.39
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39
POLB P06746 2/20 0.39
ESR1 P03372 1/20 0.39
TP53 P04637 1/20 0.39
APEX1 P27695 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3487565 0.88 HTR2A (0.46) HTR2ASLC6A4KCNH2PPARGPPARD
SCHEMBL3487706 0.88 PPARG (0.41) HTR2ASLC6A4KCNH2KMT2APPARG
SCHEMBL3488176 0.87 TEAD4 (0.46) SMN1; SMN2TDP1GFERMAPTPOLB
SCHEMBL3488035 0.87 ALDH1A1 (0.41) HPGDMAPTTP53ALDH1A1NPSR1
SCHEMBL3488380 0.86 RAF1 (0.44) SMN1; SMN2MAPTPOLBTP53ALDH1A1
SCHEMBL3487573 0.84 MAPK14 (0.40) SMN1; SMN2HTR2ALMNAHPGDMAPT
SCHEMBL3487214 0.84 ALDH1A1 (0.54) SMN1; SMN2TDP1KMT2AL3MBTL1LMNA
SCHEMBL3488332 0.83 GCK (0.46) SMN1; SMN2PPARGPPARDPPARAHTT
SCHEMBL3488354 0.83 MAPK14 (0.46) SMN1; SMN2HTR2ASLC6A4LMNAHPGD
SCHEMBL3487614 0.83 SMN1; SMN2 (0.52) SMN1; SMN2KMT2AHPGDMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2138484-B1 FUSED BICYCLIC HETEROARYL DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2015-08-26 EP disclosed
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-02-25 US disclosed
EP-2138484-A1 FUSED BICYCLIC HETEROARYL DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2009-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE PPARG, GPR119, PPARA SMN1; SMN2 4397/4885HTR2A 1485/4885SLC6A4 1449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.